Our results found that CD38 is more widely expressed than PD-1/PD-L1 in urothelial carcinoma, which may be one of the reasons why bladder cancer, with high mutational burden, has a low response rate to anti-PD-1 antibody therapy. The gene discussed is CD274; the disease is urothelial carcinoma.